Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis

• Status: Completed
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: All

Summary

To purpose of this study is to establish the efficacy and safety of RX-10045 ophthalmic solution in alleviating the signs and symptoms of allergic conjunctivitis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: C.T. Development America, Inc.
• Treatments: Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

Subjects MUST:

1. Have a positive history of ocular allergies

2. Have a positive bilateral conjunctival allergen challenge (CAC) reaction

Exclusion Criteria:

Subjects MUST NOT:

1. Have known contraindications or sensitivities to study medication or its components

2. Have any ocular condition that, in the opinion of the investigator, could affect the subject's safety or trial parameters

3. Use a disallowed medication during the period indicated prior to the enrollment or during the study

4. Be a female who is currently pregnant, planning a pregnancy, lactating, or not using a medically acceptable form of birth control